Intermountain Healthcare on Monday announced that it’s stepping closer to bringing a version of its precision medicine tool for cancer to the open market.
The health system, in fact, is pumping an additional $15 million into its spin-out Navican Genomics, which makes the TheraMap technology for matching patients with prioritized treatment options or appropriate clinical trials.
“While precision medicine has great potential to positively impact cancer patients, its use is currently fragmented at best,” Navican CEO Ingo Chakravarty said in a statement.
